|
CONCOMITANT USE OF DILTIAZEM WITH BETA BLOCKERS MAY RESULT IN ADDITIVE EFFECT ON CARDIAC CONDUCTION ; I.V. DILTIAZEM AND I.V. BETA-BLOCKERS SHOULD NOT BE ADMINISTRATION TOGETHER OR IN CLOSE PROXIMITY
|
CONCOMITANT USE OF DILTIAZEM WITH BETA BLOCKERS MAY RESULT IN ADDITIVE EFFECT ON CARDIAC CONDUCTION ; I.V. DILTIAZEM AND I.V. BETA-BLOCKERS SHOULD NOT BE ADMINISTRATION TOGETHER OR IN CLOSE PROXIMITY
|
CONCOMITANT USE OF DILTIAZEM WITH BETA BLOCKERS MAY RESULT IN ADDITIVE EFFECT ON CARDIAC CONDUCTION ; I.V. DILTIAZEM AND I.V. BETA-BLOCKERS SHOULD NOT BE ADMINISTRATION TOGETHER OR IN CLOSE PROXIMITY
|
CONCOMITANT USE OF DILTIAZEM WITH BETA BLOCKERS MAY RESULT IN ADDITIVE EFFECT ON CARDIAC CONDUCTION ; I.V. DILTIAZEM AND I.V. BETA-BLOCKERS SHOULD NOT BE ADMINISTRATION TOGETHER OR IN CLOSE PROXIMITY
|
CONCOMITANT USE OF DILTIAZEM WITH BETA BLOCKERS MAY RESULT IN ADDITIVE EFFECT ON CARDIAC CONDUCTION ; I.V. DILTIAZEM AND I.V. BETA-BLOCKERS SHOULD NOT BE ADMINISTRATION TOGETHER OR IN CLOSE PROXIMITY
|
CONCOMITANT USE OF DILTIAZEM WITH BETA BLOCKERS MAY RESULT IN ADDITIVE EFFECT ON CARDIAC CONDUCTION ; I.V. DILTIAZEM AND I.V. BETA-BLOCKERS SHOULD NOT BE ADMINISTRATION TOGETHER OR IN CLOSE PROXIMITY
|
CONCOMITANT USE OF DILTIAZEM WITH BETA BLOCKERS MAY RESULT IN ADDITIVE EFFECT ON CARDIAC CONDUCTION ; I.V. DILTIAZEM AND I.V. BETA-BLOCKERS SHOULD NOT BE ADMINISTRATION TOGETHER OR IN CLOSE PROXIMITY
|
CONCOMITANT USE OF DILTIAZEM WITH BETA BLOCKERS MAY RESULT IN ADDITIVE EFFECT ON CARDIAC CONDUCTION ; I.V. DILTIAZEM AND I.V. BETA-BLOCKERS SHOULD NOT BE ADMINISTRATION TOGETHER OR IN CLOSE PROXIMITY
|
CONCOMITANT USE OF DILTIAZEM WITH BETA BLOCKERS MAY RESULT IN ADDITIVE EFFECT ON CARDIAC CONDUCTION ; I.V. DILTIAZEM AND I.V. BETA-BLOCKERS SHOULD NOT BE ADMINISTRATION TOGETHER OR IN CLOSE PROXIMITY
|
CONCOMITANT USE OF DILTIAZEM WITH BETA BLOCKERS MAY RESULT IN ADDITIVE EFFECT ON CARDIAC CONDUCTION ; I.V. DILTIAZEM AND I.V. BETA-BLOCKERS SHOULD NOT BE ADMINISTRATION TOGETHER OR IN CLOSE PROXIMITY
|
CONCOMITANT USE OF DILTIAZEM WITH BETA BLOCKERS MAY RESULT IN ADDITIVE EFFECT ON CARDIAC CONDUCTION ; I.V. DILTIAZEM AND I.V. BETA-BLOCKERS SHOULD NOT BE ADMINISTRATION TOGETHER OR IN CLOSE PROXIMITY
|
CONCOMITANT USE OF DILTIAZEM WITH BETA BLOCKERS MAY RESULT IN ADDITIVE EFFECT ON CARDIAC CONDUCTION ; I.V. DILTIAZEM AND I.V. BETA-BLOCKERS SHOULD NOT BE ADMINISTRATION TOGETHER OR IN CLOSE PROXIMITY
|
CO-ADMINISTRATION HAS RESULTED IN INHIBITION OF HEPATIC CYTOCHROME P450 BY CIMETIDINE PRODUCING SIGNIFICANT INCREASE IN PEAK DILTIAZEM PLASMA LEVELS AND AUC ; AN ADJUSTMENT IN DILTIAZEM DOSAGE MAY BE WARRENTED
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
PROLONGATION OF QT INTERVAL MAY BE SERIOUS COMPLICATION
|
POTENTIAL FOR INCREASED SERUM LITHIUM LEVELS AND TOXICITY
|
POTENTIAL FOR INCREASED SERUM LITHIUM LEVELS AND TOXICITY
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
DILTIAZEM UNDERGOES BIOTRANSFORMATION BY CYTOCHROME P450 MIXED FUNCTION OXIDASE ; CO-ADMINISTRATION MAY RESULT IN INCREASED SERUM CONCENTRATION OF DILTIAZEM, PROBABLY DUE TO INHIBITED OXIDATIVE METABOLISM OF DILTIAZEM BY FLUVOXAMINE
|
DILTIAZEM UNDERGOES BIOTRANSFORMATION BY CYTOCHROME P450 MIXED FUNCTION OXIDASE ; CO-ADMINISTRATION MAY RESULT IN INCREASED SERUM CONCENTRATION OF DILTIAZEM, PROBABLY DUE TO INHIBITED OXIDATIVE METABOLISM OF DILTIAZEM BY FLUVOXAMINE
|
DILTIAZEM UNDERGOES BIOTRANSFORMATION BY CYTOCHROME P450 MIXED FUNCTION OXIDASE ; CO-ADMINISTRATION MAY RESULT IN INCREASED SERUM CONCENTRATION OF DILTIAZEM, PROBABLY DUE TO INHIBITED OXIDATIVE METABOLISM OF DILTIAZEM BY FLUVOXAMINE
|
DILTIAZEM UNDERGOES BIOTRANSFORMATION BY CYTOCHROME P450 MIXED FUNCTION OXIDASE ; CO-ADMINISTRATION MAY RESULT IN INCREASED SERUM CONCENTRATION OF DILTIAZEM, PROBABLY DUE TO INHIBITED OXIDATIVE METABOLISM OF DILTIAZEM BY FLUVOXAMINE
|
DILTIAZEM UNDERGOES BIOTRANSFORMATION BY CYTOCHROME P450 MIXED FUNCTION OXIDASE ; CO-ADMINISTRATION MAY RESULT IN INCREASED SERUM CONCENTRATION OF DILTIAZEM, PROBABLY DUE TO INHIBITED OXIDATIVE METABOLISM OF DILTIAZEM BY FLUVOXAMINE
|
DILTIAZEM UNDERGOES BIOTRANSFORMATION BY CYTOCHROME P450 MIXED FUNCTION OXIDASE ; CO-ADMINISTRATION MAY RESULT IN INCREASED SERUM CONCENTRATION OF DILTIAZEM, PROBABLY DUE TO INHIBITED OXIDATIVE METABOLISM OF DILTIAZEM BY FLUVOXAMINE
|
CO-ADMINISTRATION HAS INCREASED PROPRANOLOL LEVELS OF APPROXIMATELY 50% ; CONCOMITANT USE OF DILTIAZEM WITH BETA BLOCKERS MAY RESULT IN ADDITIVE EFFECT ON CARDIAC CONDUCTION ; I.V. DILTIAZEM AND I.V. BETA-BLOCKERS SHOULD NOT BE ADMINISTERED
|
CO-ADMINISTRATION HAS INCREASED PROPRANOLOL LEVELS OF APPROXIMATELY 50% ; CONCOMITANT USE OF DILTIAZEM WITH BETA BLOCKERS MAY RESULT IN ADDITIVE EFFECT ON CARDIAC CONDUCTION ; I.V. DILTIAZEM AND I.V. BETA-BLOCKERS SHOULD NOT BE ADMINISTERED
|
MAGNESIUM SALTS MAY CAUSE PROFOUND HYPOTENSION OR NEUROMUSCULAR BLOCK
|
MAGNESIUM SALTS MAY CAUSE PROFOUND HYPOTENSION OR NEUROMUSCULAR BLOCK
|
MAGNESIUM SALTS MAY CAUSE PROFOUND HYPOTENSION OR NEUROMUSCULAR BLOCK
|
MAGNESIUM SALTS MAY CAUSE PROFOUND HYPOTENSION OR NEUROMUSCULAR BLOCK
|
MAGNESIUM SALTS MAY CAUSE PROFOUND HYPOTENSION OR NEUROMUSCULAR BLOCK
|
MAGNESIUM SALTS MAY CAUSE PROFOUND HYPOTENSION OR NEUROMUSCULAR BLOCK
|
MAGNESIUM SALTS MAY CAUSE PROFOUND HYPOTENSION OR NEUROMUSCULAR BLOCK
|
MAGNESIUM SALTS MAY CAUSE PROFOUND HYPOTENSION OR NEUROMUSCULAR BLOCK
|
MAGNESIUM SALTS MAY CAUSE PROFOUND HYPOTENSION OR NEUROMUSCULAR BLOCK
|
MAGNESIUM SALTS MAY CAUSE PROFOUND HYPOTENSION OR NEUROMUSCULAR BLOCK
|
MAGNESIUM SALTS MAY CAUSE PROFOUND HYPOTENSION OR NEUROMUSCULAR BLOCK
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
POSSIBLE POTENTIATION OF BRADYCARDIA, SINUS ARREST AND AV BLOCK
|
POSSIBLE POTENTIATION OF BRADYCARDIA, SINUS ARREST AND AV BLOCK
|
INCREASED RISK OF MYOCARDIAL DEPRESSION
|
CO-ADMINISTRATION OF BETA-BLOCKER WITH DILTIAZEM MAY RESULT IN BRADYCARDIA AND HEART BLOCK AND THE LEFT VENTRICULAR AND END DIASTOLIC PRESSURE CAN RISE
|
CO-ADMINISTRATION OF BETA-BLOCKER WITH DILTIAZEM MAY RESULT IN BRADYCARDIA AND HEART BLOCK AND THE LEFT VENTRICULAR AND END DIASTOLIC PRESSURE CAN RISE
|
CO-ADMINISTRATION OF BETA-BLOCKER WITH DILTIAZEM MAY RESULT IN BRADYCARDIA AND HEART BLOCK AND THE LEFT VENTRICULAR AND END DIASTOLIC PRESSURE CAN RISE
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED SERUM LEVELS OF CARBAMAZEPINE RESULTING IN TOXICITY IN SOME PATIENTS
|
DILTIAZEM INHIBITS CYTOCHROME P450 3A ENZYME AND CO-ADMINISTRATION MAY RESULT IN INCREASED CYCLOSPORINE CONCENTRATIONS ; A REDUCTION IN CYCLOSPORINE DOSE MAY BE REQUIRED, ESPECIALLY IN RENAL AND CARDIAC TRANSPLANT RECIPIENTS
|
CO-ADMINISTRATION MAY RESULT IN INCREASED HYPOTENSIVE EFFECT
|
CO-ADMINISTRATION MAY RESULT IN INCREASED HYPOTENSIVE EFFECT
|
PHENYTOIN ENHANCES THE DRUG METABOLISM HENCE DECREASED SERUM LEVELS HAVE BEEN OBSERVED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
CALCIUM CHANNEL BLOCKERS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
CO-ADMINISTRATION OF DIGOXIN AND CALCIUM CHANNEL BLOCKERS MAY RESULT IN THE ADDITIVE EFFECTS ON AV NODE CONDUCTION
|
CO-ADMINISTRATION OF DIGOXIN AND CALCIUM CHANNEL BLOCKERS MAY RESULT IN THE ADDITIVE EFFECTS ON AV NODE CONDUCTION
|
CLOBAZAM CONCURRENT ADMINISTRATION WITH THE DRUG LEADS TO REDUCED CLEARANCE OF CLOBAZAM, HENCE THE DOSE SHOULD BE REDUCED TO ONE THIRD
|
INCREASED RISK OF CARDIOTOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|